ACA
TEVA icon

American Capital Advisory’s Teva Pharmaceuticals TEVA Stock Holding History

American Capital Advisory’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46K Buy
43
+29
+207% +$966 ﹤0.01% 701
2026
Q1 		$422 Hold
14
– – ﹤0.01% 891
2025
Q4 		$437 Hold
14
– – ﹤0.01% 796
2025
Q3 		$283 Buy
+14
New +$246 ﹤0.01% 811

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

American Capital Advisory's TEVA Position: Q2 2026 in Review

American Capital Advisory increased its Teva Pharmaceuticals (TEVA) stake by 207% in Q2 2026, buying an estimated $966 and bringing the position to 43 shares worth $1.46K. The position accounts for ﹤0.01% of the portfolio, ranked #701.

American Capital Advisory first reported a position in TEVA in Q3 2025 and has held it in 4 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • American Capital Advisory held 43 shares of Teva Pharmaceuticals worth $1.46K as of Q2 2026.
  • American Capital Advisory bought 29 Teva Pharmaceuticals shares in Q2 2026, an estimated $966.
  • Teva Pharmaceuticals made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #701 holding.
  • American Capital Advisory first reported a position in Teva Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.